A research for new cancer vaccine with heat shock protein for esophageal cancer

我们开发了一种从小鼠鳞状细胞癌SCCVII肿瘤中提取肿瘤源性热蛋白肽复合物的方法。纯化方法为Pramod K. Srivastav （method: A Companion to METHODS in酶学12,165.171(1997)）。然后利用临床标本，评估gp96的表达与食管癌手术患者的预后，分析gp96表达与手术结果的相关性。在手术标本中，73%的病例表达gp96。gp96阴性表达的患者淋巴结转移阳性率较高。单因素分析显示，gp96阳性患者生存率高于阴性患者（p=0.049）。多因素分析显示，gp96阴性是独立的预后因素（风险比：2.6,p=0.04）。在gp96阴性的病例中，转移淋巴结的数量要高得多。这些结果表明gp96可能是一个有用的食管癌生物标志物。这一结果已发表在科学杂志上。

We developed a procedure for extraction of tumor-derived HSP-peptide complex from from tumor using mouse squamous cell carcinoma SCCVII. Purification was carried out according to Pramod K. Srivastav's method (METHODS : A Companion to Methods in Enzymology 12, 165.171 (1997)). Then using clinical specimens, we evaluated the expression of gp96 and prognosis of esophageal cancer patients that underwent surgery and analyzed a correlation between gp96 expression and surgical outcome.In surgical specimens, 73% of all cases expressed gp96. A positive rate of lymph node metastases was higher in cases with negative gp96 expression. By univariate analysis, gp96 positivity indicated good survival compared to negative cases (p=0.049). By multivariate analysis, negativity for gp96 was an independent prognostic factor(Hazard ratio : 2.6, p=0.04). The number of metastatic lymph nodes was much higher in gp96 negative cases. These results indicated that gp96 can be a useful biomarker for esophageal cancer. These result has been published in a scientific journal.